- Salix Pharmaceuticals (SLXP +5.2%) and Progenics Pharmaceuticals (PGNX) finally get a date for an Advisory Committee meeting regarding the companies' appeal of the complete response letter the FDA issued for Relistor in OIC for patients with chronic pain.
- The committee will convene on March 10-11 next year, after which time action on the appeal is expected within 30 days. (PR)
- Back in June, SLXP and PGNX noted that they were "optimistic that with the [help of the] FDA and guidance from the Advisory Committee, a path forward" could be found for the drug.
at Zacks.com (Nov 10, 2014)